A prospective study analysing risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy
Latest Information Update: 21 Oct 2020
Price :
$35 *
At a glance
- Drugs Abacavir (Primary) ; Cobicistat/elvitegravir (Primary) ; Darunavir (Primary) ; Darunavir/ritonavir (Primary) ; Dolutegravir (Primary) ; Elvitegravir (Primary) ; Emtricitabine (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary) ; Tenofovir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 21 Oct 2020 New trial record
- 08 Oct 2020 Results published in the AIDS